US Patent 8367804 High affinity NY-ESO T cell receptors
Patent 8367804 was granted and assigned to Immunocore on February, 2013 by the United States Patent and Trademark Office.
All edits
Edits on 14 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 22 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 29 Nov, 2023
Golden AI
Edits made to:
Article (+386 characters)
Article
Patent abstract
The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said peptide-HLA complex of less than or equal to 1 μM and/or have an off-rate (koff) of 1×10−3 S−1 or slower.
Edits on 21 Sep, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Bent Karsten Jakobsen0
Jonathan Michael Boulter0
Peter Eamon Molloy0
Steven Mark Dunn0
Yi Li0
Edits on 15 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08367804 High affinity NY-ESO T cell receptors US Patent 8367804 High affinity NY-ESO T cell receptors
Infobox
Patent Number
083678040
Patent Number
83678040
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
083678040
Date of Patent
February 5, 2013
0Patent Application Number
131760900
Date Filed
July 5, 2011
0Patent Primary Examiner
Edits on 15 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08367804 High affinity NY-ESO T cell receptors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08367804
Date of patent
February 5, 2013
Patent application number
13176090
Date Filed
July 5, 2011
Patent primary examiner
Find more entities like US Patent 8367804 High affinity NY-ESO T cell receptors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.